BBOT
BridgeBio Oncology Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.98
+0.90%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+15.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Elmelech Idan · officer: COO & Principal Financial Ofcr | F-InKind | 343 | $7.80 |
| Jul 6, 2026 | Cobo Marc · officer: Principal Accounting Officer | F-InKind | 125 | $7.80 |
| Jul 6, 2026 | Beltran Pedro · director, officer: President and CEO | F-InKind | 1,047 | $7.80 |
| Jul 6, 2026 | Ben Yong · officer: Chief Med & Dev Officer | F-InKind | 1,047 | $7.80 |
| Jun 18, 2026 | Kelleher Raymond J. · director | A-Award | 31,675 | $7.73 |
| Jun 18, 2026 | Lebowitz Peter F · director | A-Award | 7,289 | $7.73 |
| Jun 18, 2026 | Tipirneni Praveen P. · director | A-Award | 31,675 | $7.73 |
| Jun 18, 2026 | MCCORMICK FRANK · director | A-Award | 31,675 | $7.73 |
| Jun 18, 2026 | Kumar Neil · director | A-Award | 31,675 | $7.73 |
| Jun 18, 2026 | Bauer Jake · director | A-Award | 31,675 | $7.73 |
| Jun 18, 2026 | Chen Bihua · director, 10 percent owner: | A-Award | 31,675 | $7.73 |
| May 12, 2026 | Beltran Pedro · director, officer: President and CEO | A-Award | 1,103,837 | $7.66 |
| May 12, 2026 | Elmelech Idan · officer: COO & Principal Financial Ofcr | A-Award | 758,222 | $7.66 |
| May 5, 2026 | Ben Yong · officer: Chief Med & Dev Officer | F-InKind | 1,047 | $9.03 |
| May 5, 2026 | Mehra Uneek · other: Former Officer | F-InKind | 524 | $9.03 |
| May 5, 2026 | Beltran Pedro · director, officer: President and CEO | F-InKind | 1,047 | $9.03 |
| Mar 26, 2026 | Lebowitz Peter F · director | A-Award | 63,350 | $8.72 |
| Mar 12, 2026 | Beltran Pedro · officer: Chief Scientific Officer | A-Award | 46,670 | $0.00 |
| Mar 12, 2026 | Mehra Uneek · officer: Chief Financial Officer | A-Award | 23,330 | $0.00 |
| Mar 12, 2026 | Mehra Uneek · officer: Chief Financial Officer | A-Award | 105,000 | $10 |
| Mar 12, 2026 | Beltran Pedro · officer: Chief Scientific Officer | A-Award | 210,000 | $10 |
| Mar 12, 2026 | Ben Yong · officer: Chief Med & Dev Officer | A-Award | 46,670 | $0.00 |
| Mar 12, 2026 | Ben Yong · officer: Chief Med & Dev Officer | A-Award | 210,000 | $10 |
| Jan 5, 2026 | Wallace Eli M. · director, officer: Chief Executive Officer | A-Award | 1,114,400 | $13 |
| Oct 6, 2025 | Wallace Eli M. · director, officer: Chief Executive Officer | A-Award | 1,614,400 | $12 |
| Aug 28, 2025 | Tipirneni Praveen P. · director | A-Award | 52,269 | $9.59 |
| Aug 28, 2025 | Mehra Uneek · officer: Chief Financial Officer | A-Award | 633,570 | $9.59 |
| Aug 28, 2025 | Wallace Eli M. · director, officer: Chief Executive Officer | A-Award | 499,731 | $9.59 |
| Aug 28, 2025 | Ben Yong · officer: Chief Med & Dev Officer | A-Award | 357,177 | $9.59 |
| Aug 28, 2025 | Beltran Pedro · officer: Chief Scientific Officer | A-Award | 357,177 | $9.59 |
Institutional positioning
13F filings over the trailing two quarters
New 26Increased 19Reduced 14Sold out 66
| Filer | Action | Shares | Filed |
|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | Unchanged | 17,878,594 | May 15, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 4,885,446 | May 15, 2026 |
| OMEGA FUND MANAGEMENT, LLC | Unchanged | 3,289,661 | May 15, 2026 |
| ECOR1 CAPITAL, LLC | Unchanged | 2,823,126 | May 15, 2026 |
| ALPHABET INC. | Unchanged | 2,823,126 | May 8, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 2,818,348 | May 15, 2026 |
| ENAVATE SCIENCES GP, LLC | Unchanged | 2,626,946 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 2,617,827 | Sep 2, 2026 |
| CITADEL ADVISORS LLC | Reduced | 2,528,762 | May 15, 2026 |
| NOVO HOLDINGS A/S | Increased | 2,185,923 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 2,088,297 | May 13, 2026 |
| LAURION CAPITAL MANAGEMENT LP | Reduced | 1,922,656 | May 14, 2026 |
| ARMISTICE CAPITAL, LLC | Increased | 1,328,000 | May 15, 2026 |
| AISLING CAPITAL MANAGEMENT LP | Increased | 1,018,018 | May 5, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Reduced | 868,213 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 6, 2026